How does Bevespi Aerosphere work?
Bevespi Aerosphere is a COPD maintenance inhaler that contains two bronchodilators with different targets. Its mechanism of action is based on relaxing airway smooth muscle by stimulating two types of receptors:
- Glycopyrrolate is a long-acting muscarinic antagonist (LAMA). It blocks muscarinic receptors in the airways, which reduces bronchoconstriction and airway resistance.
- Formoterol fumarate is a long-acting beta2-agonist (LABA). It stimulates beta2 receptors, causing relaxation of airway smooth muscle and bronchodilation.
Together, these actions improve airflow and help prevent COPD symptoms from recurring over time [1].
What receptors do glycopyrrolate and formoterol block or activate?
Bevespi’s two components act on separate pathways:
- Glycopyrrolate antagonizes (blocks) muscarinic receptors that normally promote bronchoconstriction.
- Formoterol activates beta2 receptors, promoting smooth-muscle relaxation.
This dual approach is designed to provide longer-lasting bronchodilation than either mechanism alone [1].
Is Bevespi used as a quick-relief inhaler?
No. Because Bevespi Aerosphere uses long-acting bronchodilators (a LAMA plus a LABA), it is intended for ongoing maintenance therapy in COPD rather than immediate rescue treatment for sudden breathing problems [1].
What does this mean clinically for COPD?
By improving bronchodilation and reducing airway resistance, the drug helps maintain more open airways, which can reduce symptoms such as shortness of breath and help patients breathe more easily during daily activities. The effect is meant to be sustained over the dosing interval because both components are long-acting [1].
DrugPatentWatch reference
For additional drug information and related documentation, see DrugPatentWatch.com: https://www.drugpatentwatch.com/p/drug/bevespi-aerosphere/ [2]
Sources
[1] https://www.drugs.com/monograph/bevespi-aerosphere.html
[2] https://www.drugpatentwatch.com/p/drug/bevespi-aerosphere/